. Among the many different causes that are associated with altered nutritional status in ESRD, the hemodialysis (HD) procedure has been associated clearly with net whole-body (WB) protein and skeletal muscle (SM) protein loss (3). This catabolic process can be reversed acutely by administration of intradialytic parenteral nutrition (IDPN) (4). Despite its shown anabolic effects, IDPN administration is costly, and patient eligibility for this type of nutrition support is widely restricted. In addition, the anabolic effects of IDPN seem to be limited to the period of administration, with no evidence of persistent anabolism once its infusion is shut off (4).
P oor nutritional status and muscle wasting are common in patients with ESRD and are associated with increased hospitalization and death (1, 2) . Among the many different causes that are associated with altered nutritional status in ESRD, the hemodialysis (HD) procedure has been associated clearly with net whole-body (WB) protein and skeletal muscle (SM) protein loss (3) . This catabolic process can be reversed acutely by administration of intradialytic parenteral nutrition (IDPN) (4) . Despite its shown anabolic effects, IDPN administration is costly, and patient eligibility for this type of nutrition support is widely restricted. In addition, the anabolic effects of IDPN seem to be limited to the period of administration, with no evidence of persistent anabolism once its infusion is shut off (4) .
Oral nutritional supplementation (PO) is a promising anabolic intervention in chronic HD (CHD) patients because of its potentially more physiologic and affordable characteristics. Despite its potential benefits, only limited studies have evaluated the effects of intradialytic PO administration on protein metabolism in CHD patients, and none to our knowledge has compared its metabolic effects with those of IDPN in CHD patients with deranged nutritional status.
In this study, we hypothesized that administration of intradialytic PO supplementation would compensate WB and SM protein derangements as a result of the HD procedure, resulting in net protein anabolism. We further hypothesized that these beneficial effects would be less than what is observed with IDPN administration. To test these hypotheses, we studied protein metabolism in eight CHD patients with deranged nutritional status during three separate HD sessions-with PO, with IDPN, and with no intervention (control)-using stable isotope infusion techniques.
Materials and Methods

Patients
Patients were recruited from the Vanderbilt University Outpatient Dialysis Unit. Inclusion criteria consisted of patients who were on CHD for Ͼ6 mo, were using a biocompatible HD membrane (Fresenius F80; Fresenius USA, Lexington, MA), had double-pool Kt/V Ն1.4, were on a thrice-weekly HD program, and had signs of deranged nutrition status, as defined by levels of several serum proteins below National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Nutritional Guidelines recommended targets, including serum albumin Ͻ4 g/dl, serum prealbumin Ͻ30 mg/dl, cholesterol Ͻ150 mg/dl, and serum transferrin Ͻ150 mg/dl for 3 consecutive months before enrollment.
b Active infectious disease, hospitalization within the last 3 mo, recirculation in the vascular access and/or vascular access blood flow Ͻ750 ml/min, and use of steroids and/or immunosuppressive agents were exclusion criteria. The Institutional Review Board of Vanderbilt University approved the study protocol, and written informed consent was obtained from all study patients. Patient characteristics are shown in Tables 1 and 2 .
Design
This was a randomized, 1 prospective, crossover study. After written informed consent was obtained and the inclusion and exclusion criteria were reviewed, eligible patients were assigned a random computergenerated sequence of study protocols that included IDPN, control, and PO combinations. All patients who participated in this study were randomly assigned and participated in all protocols, with at least 4 wk between each study, to allow for total clearance of the stable isotopes. Within 1 wk before each study, dual-energy x-ray absorptiometry was performed to estimate lean and fat body masses.
The patients were admitted to the General Clinical Research Center (GCRC) the day before the study at approximately 7 p.m., received a meal from the GCRC bionutrition services upon admission, and remained fasting after that. The last meal was given at least 10 h before the initiation of the study for all patients and consisted of 18% protein and 30% lipids. Energy intake was kept at maintenance levels on the basis of the Harris-Benedict equation and each patient's gender, height, weight, and activity levels.
A schematic diagram of the metabolic study day protocol is depicted in Figure 1 . Each metabolic study consisted of a pre-HD phase (a 2-h equilibration phase followed by a 0.5-h basal sampling phase), a 4-h HD phase, and a 2-h post-HD phase. A dialysis catheter was placed at the venous site of the arteriovenous (AV) shunt of the forearm at 6 a.m. to collect a baseline blood sample (to assess baseline biochemical nutritional markers and isotopic backgrounds) and then to initiate the isotope infusion. Arterial vascular access that was obtained through the arterial side of the AV shunt was used to perform HD and to sample arterial blood. The venous site of the AV shunt was used to infuse the isotopes. Another catheter was placed in a deep vein (with a retrograde insertion) of the contralateral forearm to sample blood draining the forearm muscle bed. At the start of the infusion, patients received a bolus injection of NaH 13 CO 3 (0.12 mg/kg), l-(1-13 C) leucine (7.2 mol/kg), and l-(ring-2 H 5 ) phenylalanine (7.2 mol/kg) to prime the CO 2 , leucine, and phenylalanine pools, respectively. A continuous infusion of leucine (0.12 mol/kg per min) and phenylalanine (0.12 mol/kg per min) isotopes then was started and continued throughout the remainder of the study. Constant infusion of isotopes continued throughout the study. Blood samples were collected once before the start of the study, three times during the basal sampling phase, six times during HD, and three times during the post-HD phase. Simultaneous with each blood sample, breath samples were collected from the patients via a Douglas bag with duplicate 20-ml samples placed into nonsiliconized glass Vacutainer tubes for measurement of breath 13 CO 2 enrichment. Patients were asked to breathe through a mask for 1 min each time blood was collected. In addition, forearm blood flow was estimated using capacitance plethysmography (D.E. Hokanson, Inc., Bellevue, WA).
In the protocol using IDPN, its administration was started 30 min after HD initiation and continued through the end of HD. Administration of PO was divided into three equal doses; the first dose was administered 30 min after the start of HD, the second dose was administered 1.5 h after the start of HD, and the third dose was administered 2.5 h after HD was initiated. During the control protocol, no nutrition was given throughout the study. The IDPN treatment was based on existing recommendations (8) . The solution consisted of amino acids (AA) at a concentration of 15%, dextrose at a concentration of 50%, and lipids at a concentration of 20%. The AA and dextrose solutions were infused at a rate of 113 ml/h, and the lipids solution was infused at a rate of 37 ml/h, delivering approximately 525 ml and 188 kcal/h, and consisted of 59 g of AA, 26 g of lipids, and 197 g of carbohydrates.
Intradialytic PO supplementation was designed in attempts to match the volume and protein content provided with IDPN, consisting of two cans of a specialized complete nutrition for electrolyte and fluid restrictions (NEPRO, Ross Products Division, Abbott Laboratories Inc., Columbus, OH) with the addition of 5 spoons of powder protein (PROMOD, Ross Products Division) to prescribe the same protein amount provided by IDPN. The PO mixture contained 474 ml and 1090 kcal and consisted of 57 g of AA, 48 g of lipids, and 109 g of carbohydrates. During the control study, no nutritional supplementation was given.
The following were the composition of essential AA provided with IDPN and PO in grams, respectively: isoleucine (2.962 and 3.011), leucine (4.113 and 5.754), valine (3.797 and 3.459), lysine (4.667 and 4.815), phenylalanine (4.113 and 2.560), histidine (3.536 and 1.305), methionine (2.962 and 1.513), threonine (2.962 and 3.286), and tryptophan (0.989 and 0.873). Isoleucine, leucine, and valine are branchedchain AA (BCAA).
During each study, patients were dialyzed for 4 h with blood flow of 400 ml/min and dialysate flow of 500 ml/min. Ultrafiltration rates were determined by the patients' needs and estimated dry weight and were similar during all studies. The composition of the dialysate used during the study was identical for all treatments and consisted of 139 mEq/L sodium, 2 mEq/L potassium, 2.5 mEq/L calcium, 200 mg/dl glucose, and 39 mEq/L bicarbonate. Once HD was finished, dialysis lines were disconnected and the 2-h post-HD phase ensued. After the post-HD phase, all catheters were removed, and the patients were b Several terminologies have been proposed for this complex syndrome of low visceral and/or somatic protein stores that are associated or not with inflammatory response. These include uremic malnutrition (5), malnutrition inflammation atherosclerosis syndrome (6), malnutrition inflammation complex syndrome (7), and, more recently, kidney disease wasting (Denis Fouque, personal communication, Dénutrition des Maladies Chroniques Ho ឈpital, Lyon, France, April 27, 2006). Although a consensus on terminology is yet to be achieved, the term deranged nutritional status is used as reference in this article. given a meal and observed at the GCRC until stable, upon which they were discharged.
Analytical Procedures
Blood samples were collected into Venoject tubes that contained 15 mg of Na 2 EDTA (Terumo Medical Corp., Elkton, MD). All analytical procedures, including nutritional biochemical markers, were performed as described previously (3, 4) . Individual AA were placed into groups for analysis purposes. These groups included essential AA (EAA; the sum of arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), total AA (TAA; the sum of all individual AA), and nonessential AA (NEAA; the difference between TAA and EAA).
Plasma enrichments of ( 13 C) leucine, ( 13 C)ketoisocaproate, and (ring-2 H 5 ) phenylalanine were determined using gas chromatography/mass spectrometry (Hewlett-Packard 5890a GC and 5970 MS, San Fernando, CA), as described previously (3, 4) . The plasma enrichments of (ring-2 H 5 ) phenylalanine and, therefore, the muscle calculations were available for only six of the eight studied patients.
Calculations
Net SM protein balance (synthesis Ϫ breakdown) was determined by dilution and enrichment of phenylalanine across the forearm as described by Gelfand and Barrett (9) and as previously reported (3, 4) . The steady-state rates of total WB leucine appearance (Ra) were calculated by dividing the ( 13 C)leucine infusion rate by the plasma ( 13 C)ketoisocaproate enrichment (10) as described previously (3, 4) .
Statistical Analyses
For each protocol, mean variables across all time points for each study phase (before, during, and after HD) were averaged to represent each study phase average per patient. Values that are presented in the text and figures are means Ϯ SEM, unless otherwise noted. The goal of this study was to compare the two modes of nutritional supplementation (IDPN and PO) with no intervention (control) at each study phase separately, rather than to examine time trends for each variable and their interaction throughout the study phases. Therefore, for comparisons of variables among study protocols at each study phase, a general linear model ANOVA was performed, selecting study protocol as a fixed factor and repeated contrast. Post hoc analyses of multiple comparisons were completed by using the least significant difference test, which is the equivalent to multiple t test between all paired groups. Comparisons of baseline biochemical variables among the three groups were completed by a one-way ANOVA test. P Ͻ 0.05 was required to reject the null hypothesis of no difference between the means. The software SPSS (version 14; SPSS Inc., Chicago, IL) was used for all analyses. Table 2 depicts baseline biochemical nutritional markers for the three study protocols: control, PO, and IDPN. As can be seen, these measurements were similar among the protocols, and there were no statistical differences. As suggested by the biochemical markers in Table 2 , the population studied was in an overall deranged nutritional status. Measurement of preand post-HD blood chemistries, including BUN, showed expected changes after HD treatment without any significant difference among the three HD sessions within patients (data not shown). Table 3 shows the results for glucose and metabolic hormones for the three study protocols. In the pre-HD phase, there were no statistically significant differences in glucose or any of the metabolic hormones among protocols. During HD, plasma insulin concentrations were significantly higher with both PO and IDPN compared with control (P ϭ 0.027 for IDPN versus control and 0.001 for PO versus control). Insulin concentration remained significantly elevated in the post-HD phase for the PO protocol but not for the IDPN protocol, compared with control (P ϭ 0.008 and 0.590, respectively). As a result, insulin levels were statistically significantly higher when PO and IDPN protocols were compared in the post-HD phase (P ϭ 0.025). Plasma glucose levels were significantly higher during HD for IDPN and PO compared with control although at a higher extent with IDPN (P Ͻ 0.001 and 0.037, respectively). In the post-HD phase, glucose levels remained significantly higher in the PO protocol compared with IDPN and control (P ϭ 0.002 and 0.007, respectively), but glucose levels were not different between IDPN and control. There were no statistically significant differences among protocols in any of the other metabolic hormones throughout the entire study period.
Results
Blood Chemistries
Glucose and Metabolic Hormones
Plasma AA
There were no statistically significant differences among study protocols during the pre-HD phase for all plasma AA However, plasma concentrations of all groups of AA were significantly higher during HD for both IDPN and PO compared with control (P Ͻ 0.001 for all comparisons), as shown in Figure 2 . The differences between IDPN and PO were numerically but not statistically significantly higher for IDPN than PO for BCAA (P ϭ 0.072), EAA (P ϭ 0.067), and NEAA (P ϭ 0.065) and were statistically significantly higher only for the TAA group (P ϭ 0.001). During the post-HD phase, the concentrations of all groups of AA were significantly higher in the PO protocol compared with both control and IDPN. Specifically, the post-HD plasma concentra- Forearm AA Uptake Table 4 shows the forearm uptake of AA by functional groups. In the pre-HD phase, no statistically significant differences were observed among protocols for BCAA (P ϭ 0.488 for both IDPN and PO versus control), EAA (P ϭ 0.862 for IDPN versus control and 0.884 for PO versus control), NEAA (P ϭ 0.537 for IDPN versus control and 0.750 for PO versus control), and TAA (P ϭ 0.538 for IDPN versus control and P ϭ 0.815 for PO versus control). During HD, however, forearm uptake of all grouped AA were significantly improved, changing from AA muscle loss to accretion, with both PO and IDPN compared with control ( Table 5 shows the dynamic components of WB protein homeostasis for the three study protocols at pre, during, and post-HD phases. In the pre-HD phase, there were no statistically significant differences among protocols for synthesis (P ϭ 0.730 for IDPN versus control and 0.626 for PO versus control), proteolysis (P ϭ 0.947 for IDPN versus control and 0.655 for PO versus control), and net balance (P ϭ 0.662 for IDPN versus control and 0.722 for PO versus control). Figure 3 depicts data during HD. As seen, the infusion of IDPN and administration of PO during HD resulted in significantly higher protein synthesis compared with control (P ϭ 0.012 for IDPN versus control and 0.001 for PO versus control). Whereas proteolysis was numerically lower for both IDPN and PO compared with control, it was only statistically significantly lower, albeit slightly, for the IDPN versus control comparison (P ϭ 0.040 for IDPN versus control and 0.218 for PO versus control). As a result, the net WB protein balance was highly positive (anabolism) with both modes of nutrition support therapies as compared with control (P ϭ 0.002 for IDPN versus control and Ͻ0.001 for PO versus control). In the post-HD phase, protein synthesis remained statistically significantly higher, although slightly, for PO compared with both IDPN and control (P ϭ 0.012 for PO versus control and 0.022 for PO versus IDPN). In the post-HD phase, proteolysis also was higher for the PO protocol compared with both IDPN and control, although these differences did not reach statistical significance (P ϭ 0.061 for PO versus control and 0.059 for PO versus IDPN). The net result therefore was a trend toward pre-HD values for both control and IDPN protocols but not for PO, for which the net balance was significantly more negative compared with control and IDPN (P ϭ 0.012 for PO versus control and 0.039 for PO versus IDPN). Table 6 depicts the dynamic components of the forearm muscle protein homeostasis. At baseline, there were no statistically significant differences among the study protocols. During HD, muscle protein synthesis was only numerically higher for both IDPN and PO compared with control (P ϭ 0.445 and 0.543, respectively), but because these numerically higher rates exceeded the rates of proteolysis, the net result was positive muscle protein metabolism (protein accretion) for both IDPN and PO compared with control (P ϭ 0.005 for IDPN versus control and 0.009 for PO versus control; Figure 4 ). In the post-HD phase, the positive net balance persisted for PO but not for IDPN, resulting in significant improvements in the net forearm muscle balance for PO compared with both control and IDPN (P ϭ 0.039 for both comparisons).
WB Protein Metabolism
Forearm Muscle Protein Metabolism
Discussion
Our study was designed to examine the effectiveness of oral nutritional supplementation that is administered during the HD procedure in a selected group of CHD patients with findings of deranged nutritional status. Our results indicate that intradialytic PO supplementation is capable of reversing the HD-associated net WB and SM protein catabolism. Our results further indicate that PO administration is similarly effective to IDPN at maintaining a positive WB and SM net protein balance during HD, consistent with our study hypothesis. Because these findings are observed in a group of high-risk CHD patients with deranged nutritional status, they have potential clinical relevance and need to be confirmed by long-term nutritional studies in this patient population. Most patients with ESRD experience some degree of a complex syndrome that includes low concentrations of serum proteins and/or lean body mass loss and often is associated with increased serum concentrations of inflammatory markers. This occurs despite preventive methods such as adequate dosage of dialysis and intense nutritional counseling. The well-established link between signs of deranged nutritional status and increased risk for hospitalization and death in CHD patients (11,12) necessitates nutritional interventions above and beyond these traditional preventive methods. We previously reported that IDPN is highly effective in reversing HD-associated catabolism, at least in the acute setting. Although the logical extension of these studies would be a long-term clinical trial to examine the prolonged use of IDPN, such an approach is not attractive primarily because of certain logistical barriers that are associated with the use of IDPN, at least in the United States. Specifically, IDPN is costly, and its prescription requires overcoming major regulatory hurdles. Furthermore, there are indications that IDPN might be associated with certain adverse effects such as nausea, hypoglycemia, and hyperlipidemia and that its beneficial effect on protein turnover is limited to the period in which it is being administered (13, 14) . Overall, these drawbacks decrease the enthusiasm for the use of IDPN in the long term and suggest that alternative approaches of nutrition support and the treatment of deranged nutritional status should be explored.
Several small-scale, short-term studies, including a few controlled trials, indicate that oral nutritional supplementation administration can be an effective approach to preventing deranged nutritional status (15) (16) (17) . In addition, a few studies indicated benefits of PO given during HD to treat the HDassociated protein catabolism (4, 18) . A study by Veeneman et al. (18) examined the effects of feeding during HD on WB protein balance in a group of well-nourished CHD patients. The feeding was in the form of yogurt, cream, and protein-enriched milk powder, given as six equal portions during the HD procedure as well as on a nondialysis day. Their results showed that consumption of a protein-and energy-enriched meal during HD resulted in a positive protein balance to the same extent as on a nondialysis day. Of note, the investigators did not examine SM protein balance in this study. Although our results are in general agreement with that of Veeneman et al., our study further extends these findings to a target patient population with deranged nutritional status and provides critical information regarding the different components of WB protein metabolism, namely SM.
An additional novel aspect of our study is that we assessed the relative protein metabolic effects of two modes of nutritional support: PO and IDPN. Our results are consistent with our null hypothesis, indicating that IDPN did not provide a significantly higher anabolic effect over intradialytic PO in reversing HD-associated protein catabolism, in both the WB and SM compartments. Furthermore, the beneficial effects of oral supplementation extended to the post-HD period in the muscle compartment, providing an additional positive effect above and beyond of what is observed with IDPN. Taken together, these results strongly indicate that PO nutritional supplementation is an excellent strategy to prevent and potentially treat deranged nutritional status. When the financial advantages of oral supplementation over IDPN are included in the final analysis, it is reasonable to suggest that PO supplementation would be the treatment of choice for all CHD patients that require nutritional intervention. Nonetheless, we acknowledge that our findings are from a small-scale metabolic study and as such need to be confirmed by long-term nutritional trials in the CHD population with deranged nutritional status. Furthermore, the results of this study may not be generalizable to nonblack CHD patients with low fat and lean body masses, because these were not characteristics of the population studied herein. Our study clearly indicates that nutritional supplementation, administered either intravenously or orally, can compensate adequately for the catabolic effects of the HD procedure. Although we did not specifically study the cellular and molecular mechanisms that are associated with these responses, it is likely that the increased plasma concentrations of AA is one of the critical components that drive the positive protein balance as evidenced by increased plasma AA during IDPN and maintenance of AA levels during PO administration (19, 20) . Of note, these increases were observed despite potentially increased AA losses into the dialysate (21) . However, studies that have examined nutrient supplementation under many different conditions have demonstrated that muscle protein stores are not determined by nutrient intake alone. Insulin action also plays an important role in controlling nutrient deposition (22) . Specifically, circulating insulin influences carbohydrate homeostasis by altering muscle glucose transport (23, 24) and utilization (25) and regulates protein dynamics by stimulating AA transport, promoting WB and muscle protein synthesis, and inhibiting proteolysis (22) . These effects are amplified when AA availability is increased simultaneously with insulin (22) . In our study, increased insulin concentration and ample AA availability as a result of IDPN and PO decreased WB proteolysis and increased WB protein synthesis, suggesting that the effects likely are the result of both increased AA availability and increased insulin action, at least in part. Another indication that insulin plays a critical role in the metabolic response that is associated with nutritional supplementation is that once the IDPN infusion was stopped, the insulin concentration decreased back to baseline values with a simultaneous reversal of the net protein balance to baseline levels, whereas insulin concentrations remained elevated during the post-HD period in the PO protocol with simultaneously increased SM net protein balance. However, the WB proteolysis also increased during the post-HD period in the PO protocol without a clear explanation. It is possible that the characteristics of the patient population studied, such as deranged nutritional status, might have led to certain unrecognized abnormalities in substrate metabolism. In addition, although speculative, it is possible that provision of PO might have suppressed signaling for the production of some of the acute-phase reactants, which constitutes a significant portion of WB protein turnover. In any case, our results indicate that PO provided clear benefits in the muscle protein homeostasis compared with IDPN both during dialysis and postdialysis periods.
It also is important to note that in this study, oral and parenteral nutritional supplementations were not exactly matched for carbohydrate, lipid, and AA supplies. However, both protocols provided carbohydrate and lipid amounts well above the minimum level required for each to provide any significant effect on protein metabolism. In these conditions, we believe that the differences in energy supplies would have little effect on protein metabolism. Similarly, there was minimal difference in the amount of EAA, including BCAA, that was provided in the two nutritional regimens. We believe that these minimal differences were unlikely to have affected the results. This is consistent with the observation that plasma EAA concentrations were not statistically significantly different between IDPN and PO protocols.
Conclusion
The results of this study indicate that intradialytic PO supplementation is similarly effective as IDPN in preventing HDassociated net WB and SM protein catabolism and has the additional benefit of persistent anabolic effects in the SM after the HD procedure is complete. Because these findings were observed in a group of high-risk CHD patients with deranged nutritional status, they have significant implications for the nephrology clinical practice. Further studies to examine both the mechanisms of action in different patient populations and long-term effects of PO supplementation are warranted, specifically in CHD patients, who are at additional risk for mortality and morbidity, partly as a result of deranged nutritional status.
